Literature DB >> 24790033

Effect of left atrial activity after the maze procedure on clinical and echocardiographic outcomes.

Seung-Jung Park1, Young Keun On, June Soo Kim, Dong Seop Jeong, Wook Sung Kim, Kiick Sung, Young Tak Lee, Pyo Won Park.   

Abstract

BACKGROUND: Although the maze procedure reduces the risk of adverse cardiac events, the clinical importance of post-maze left atrial (LA) activity on long-term surgical outcomes is not well defined. METHODS AND
RESULTS: Between January 2000 and December 2009, 416 consecutive patients with sinus conversion after a modified Cox III procedure with cryoablation were enrolled and subdivided into patients with restored LA activity (group ReA; n=231) and those without LA activity (group NoA; n=185) assessed using Doppler echocardiographic examination at 3-6 months after the maze procedure. During the long-term follow-up (4.6±2.6 years), the NoA group showed more frequent major adverse events (P=0.001) including cardiac death (P=0.145), heart failure events (P=0.032), and thromboembolic stroke (P=0.048) than the ReA group. In multivariate analysis, lack of LA activity was associated with a 2.2-fold increased risk for major adverse events (95% confidence interval [CI], 1.1-6.8; P=0.029) and with a 2.4-fold increased risk for late progression of tricuspid regurgitation (95% CI, 1.0-3.5; P=0.041).
CONCLUSIONS: Absence of LA activity after the maze procedure was independently associated with a significantly increased risk of major adverse events and late progression of tricuspid regurgitation.

Entities:  

Mesh:

Year:  2014        PMID: 24790033     DOI: 10.1253/circj.cj-13-1390

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  1 in total

1.  Impact of ablation duration on rhythm outcome after concomitant maze procedure using cryoablation in patients with persistent atrial fibrillation.

Authors:  Dong Seop Jeong; Ji Hoon You; Chang-Seok Jeon; Pyo Won Park; Kiick Sung; Wook Sung Kim; Young Tak Lee
Journal:  J Cardiothorac Surg       Date:  2017-07-24       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.